Articles tagged with Cervical Cancer
A study published in PLOS ONE found that nitrile gloves can effectively prevent the collapse of speculums during pelvic exams, reducing discomfort and misdiagnosis. The researchers used a physical model to test the effectiveness of gloves versus condoms, with promising results.
A study published in Cell Host and Microbe found that gender-neutral HPV vaccination is effective in preventing cervical cancer by inducing a stronger herd immunity. The vaccine protects against high-risk HPV types 16 and 18, which cause 70% of all HPV-related cervical cancers, and also provides cross-protection against low-risk types.
Research by George Mason University found that women with physical disabilities have lower cervical cancer screening rates, highlighting the need for improved access to preventive health services. The study's findings also reveal disparities in screening rates among different types of disabilities.
A team of researchers at Kyoto University has found that a deficiency in the enzyme B4GALT3 inhibits tumor growth in mice. The study shows that reduced glycosylation on T cell surfaces correlates with increased CD8+ immune cells infiltrating tumors.
The INTERLACE trial found that a short course of induction chemotherapy prior to chemoradiation significantly improves survival and reduces recurrence in locally advanced cervical cancer patients. The study results show a 35% reduction in recurrence, with 80% of patients alive and 73% without cancer return or spread after five years.
Researchers documented a steady increase in cervical cancer incidence and death rates in Appalachian Kentucky from 2000 to 2019. The region's cervical cancer death rate is now twice the national average, with distant-stage cancers increasing by 5.5% per year.
Researchers discovered that lactate-producing intratumoral bacteria drives resistance to radiation therapy. Cancer cells respond to radiation by rewiring metabolic signaling pathways using lactic acid instead of glucose.
A new cancer immunotherapy that targets two immune-evading tumor tactics has shown promising results in an early clinical trial. The drug, tebotelimab, blocks both PD-1 and LAG-3 proteins, leading to a double-digit response rate in patients with advanced solid tumors or blood cancers.
A multilevel primary care intervention, including electronic health record reminders and patient outreach, improved timely follow-up of overdue abnormal cancer screening test results for breast, cervical, colorectal, and lung cancer. The intervention was found to be effective in reducing missed screenings.
Researchers found that short-form videos on TikTok can inform and encourage women to get regular pap tests, particularly when created by doctors. The studies also showed that autonomy-supportive messages improved attitude toward the message and engagement intention.
Researchers found that using electronic prompts during appointment scheduling for seasonal flu and COVID-19 vaccines can identify willing participants for HPV and shingles vaccines. Only 30% of those booking for these vaccines were already vaccinated against HPV, presenting a significant opportunity for targeted campaigns.
Two liquid biopsy tests identified patients with a high risk of cervical cancer recurrence after chemoradiation treatment, allowing for earlier detection and potential improvement in outcomes. The tests detected HPV ctDNA in the blood of patients with residual disease, providing insight before tissue biopsy becomes possible.
Patients who engage in regular sexual activity or vaginal dilation have a lower risk of long-term side effects, including vaginal stenosis. Regular dilation and/or sex were associated with lower risk of moderate-grade vaginal shortening and narrowing five years after treatment.
A new Canadian guideline aims to promote health equity among marginalized groups by providing 16 preventive care recommendations. The guidelines focus on removing barriers to healthcare, prioritizing people from disadvantaged groups, and improving access to essential screenings and interventions.
A new study by Ohio State University found that most gynecologic cancer-related content on TikTok is poor in quality and accuracy. The majority of the content, over 73%, was deemed inaccurate and of poor educational quality, with racial disparities also present.
Chung-Ang University researchers create an electrochemical DNA biosensor that detects HPV-16 and HPV-18 with high specificity, facilitating early diagnosis of cervical cancer. The sensor uses a graphitic nano-onion/MoS2 nanosheet composite to enhance conductivity.
Scientists at Montefiore Einstein Cancer Center have developed a novel HPV test that detects cervical adenocarcinoma and its precursor lesions with high sensitivity. The test assesses methylation levels in cervical tissue samples, offering a more accurate detection method for this common type of cancer.
A new study estimates that cancer screenings have saved the US at least $6.5 trillion and led to 12 million more years of life, with significant economic impact from breast, colon, cervical, and lung cancer screenings.
A study finds that additional recommended cervical cancer screenings before birth are associated with an increased risk of preterm delivery. The findings suggest that cervical cancer screening guidelines should consider the downstream implications for preterm delivery risk when weighing population-level costs against benefits.
Researchers from Korea University Medicine have discovered a potential therapeutic target for overcoming cisplatin resistance and neuropathic pain in cervical cancer. By inhibiting TRPV1, they found that resistant tumors became vulnerable to cisplatin, improving the outlook for patients.
Rice University engineers developed a low-cost, point-of-care DNA test for HPV infections that can be used to screen for cervical cancer. The test, which requires just two pieces of equipment and delivers results in 45 minutes, has the potential to make cervical cancer screening more accessible in low- and middle-income countries.
A new study published in the Journal of the American College of Surgeons found that people who live in historically redlined areas are less likely to be screened for breast, colorectal, and cervical cancer. The legacy of redlining continues to contribute to significant disparities in cancer screening rates.
A new study found significant reductions in breast, colorectal and prostate cancers as well as melanoma diagnoses in Alberta during the COVID-19 pandemic. Diagnoses dropped by 43% for melanoma, 36% for colorectal and prostate, and 33% for breast cancer during the 'state of emergency' phase.
A new study found that obesity is associated with an increased risk of certain cancers, with stronger links in female patients for gallbladder and endometrial cancer. The study also revealed differential effects between sexes on colorectal, esophageal, and liver cancer.
A new study published by LSU Health New Orleans found that a diet high in fruits, dark-green vegetables, and beans can significantly lower the risk of genital high-risk-HPV infection, which is associated with cervical cancer. The research also showed that women who eat healthily tend to practice other healthy behaviors.
A US-based clinical trial found that mailing high-risk human papillomavirus (hrHPV) sampling kits to low-income, under-screened women increased cervical cancer screening uptake by nearly double. The study used intensive community outreach campaigns and mailed HPV kits with effective help scheduling in-person appointments.
Scientists have identified a specific gene mutation that triggers an inflammatory cascade, driving the development of treatment-resistant cancers. The study reveals a molecular circuitry by which mutations in the STK11 gene cause inflammation to spiral out of control.
Researchers found mailing HPV self-collection tests and offering assistance improved cervical cancer screening nearly two-fold among low-income women. Screening uptake increased to 72% among women who received mailed HPV kits, compared to 37% for those with scheduling assistance alone.
A Phase 3 trial found that mailing HPV self-collection kits and scheduling assistance increased cervical cancer screenings among under-screened, underserved women. The study demonstrated the effectiveness of this approach in breaking down access barriers to screening.
A new study found that remote outreach involving interactive education and follow-up support via telephone increased breast, cervical, and colorectal cancer screening rates among rural women. The combination of a remotely delivered interactive DVD and patient navigation services resulted in a six-fold increase in screenings.
Researchers at Oregon State University have created a new model for evaluating potential cervical cancer drugs. The study, led by Kaitlin Fogg, enables the simultaneous and rapid testing of multiple drug compounds, opening the door to large-scale screenings that can uncover new therapies and personalized medicine options.
Researchers identified ARID1A and PIK3CA as potential targets for drug development in recurrent and metastatic cervical cancer. The study found that these mutations were associated with improved survival rates, suggesting their potential as new treatment options.
The NRG-GY017 trial found that atezolizumab improved 2-year disease-free survival rates (79% vs. 59%) and pathologically complete or partial responses (69% vs. 40%) for patients with locally advanced cervical cancer. The study also showed a favorable immune response, including positive PD-L1 scoring and T-cell receptor clonal expansion.
A study published in The Lancet Public Health found that women with mental illness are twice as likely to develop cervical cancer due to low screening rates and increased incidence of precancerous lesions. Researchers highlight the need for proactive measures to address inequality in care.
Researchers found that miR-145 suppresses cervical cancer cell growth and inhibits aerobic glycolysis. Targeting miR-145 is expected to be an effective strategy for cervical cancer treatment, according to the study.
A study of 19,000 female participants found mailing HPV self-sampling kits to be an efficient way to increase screening rates among eligible women. This cost-effective approach supports the use of mailed HPV kits as an outreach strategy for U.S. healthcare systems.
A new smoking cessation intervention, MAPS, has been shown to increase smoking abstinence rates in patients with cervical cancer or precancerous disease by over two-fold. The study found that extended treatment and sustaining the program may be necessary for long-term abstinence.
A study of nearly 24,000 individuals reveals insurance status as a modifiable risk factor for racial and ethnic inequities in advanced cervical cancer diagnosis. Expanding access to care may mitigate these inequities.
A global study aims to better understand the burden of Human papillomavirus (HPV) among girls and women in low- and lower middle-income countries. The study will inform effective strategies to prevent infection and introduce HPV vaccine into national programs, protecting the health of girls and women and reducing rates of cervical cancer.
Researchers found a connection between arthritis flare-ups and periodontitis, suggesting that regular dental check-ups could help prevent rheumatoid arthritis. The study also identified potential therapeutic targets for cancer, including the use of mouthwash to prevent flares.
The HALP score, a novel immune-nutritional marker, has been linked to prognostic ability in different cancer types. It integrates indicators of immune status and nutritional status, showing promise as a cost-effective biomarker.
A recent study by the University of Kentucky Markey Cancer Center validates a new radiopharmaceutical compound as a viable treatment option for patients with advanced cervical cancer. The radioactive drug, 212Pb-DOTAM-GRPR1, targets gastrin-releasing peptide receptor, a protein expressed by cancer cells.
Researchers identify the minimum contribution of TACC3 for FGFR3-TACC3 fusion protein activation, revealing a novel target for treating FGFR translocation-driven cancers. The study shows that clinically identified FGFR3-TACC3 fusion proteins differ in biological activity depending on specific breakpoints.
The ESMO Gynaecological Cancers Congress 2023 will present the latest treatments and insights for ovarian, uterine, cervical, and rare gynaecological cancers. Around 80 studies will be presented on strategies to overcome PARP inhibitors mechanisms of resistance in ovarian cancer.
The institutions will develop trials to screen cervical cancer patients in low-resource countries, aiming to prevent advanced cancer. The collaboration aims to achieve the World Health Organization's goal of eliminating cervical cancer by adapting and innovating prevention strategies.
A new study reveals that nearly one in five new cervical cancers diagnosed from 2009-2018 were in women 65 and older, with late-stage diagnoses increasing up to age 79. The study suggests that current screening guidelines may be failing these women, leading to lower survival rates.
The EMBRACE-I study demonstrated the superiority of personalized brachytherapy in treating locally advanced cervical cancer. A targeted approach using magnetic resonance imaging-defined tumor volume resulted in a high tumor control rate and low risk of recurrence.
Researchers at the University of Tokyo have developed artificial DNA that can target and kill cancer cells by binding to microRNA molecules. The DNA triggers an immune response that not only kills cancer cells but also prevents further growth of cancerous tissue.
A recent study found that many young cancer survivors decline HPV vaccination due to concerns about safety, importance, and timing. The research aims to address these concerns and provide health care providers with messaging tools to encourage survivors to receive the vaccine.
Despite decreases in some high-income countries, the global cervical cancer burden remains high due to inadequate screening and vaccination programs in low- and middle-income countries. The study highlights the need for scaling up HPV vaccination and screening efforts globally to achieve the WHO's 2030 elimination target.
Researchers found that lncRNA MVIH is overexpressed in cervical cancer tumors and associated with younger age, lymph node metastasis, tumor invasion depth, and squamous cell type. This suggests its potential as a diagnostic biomarker for cervical cancer.
A systematic review of national clinical practice guidelines in Europe found that fewer than half include HIV testing recommendations for patients with medical conditions indicating HIV infection. This omission hinders efforts to stop the spread of HIV through timely diagnosis, affecting the lives of people living with HIV.
A new study published in JAMA Internal Medicine suggests that more public health data is needed on the utilization of cervical cancer screening-associated services among older women. The analysis showed that over 1.3 million women received cervical cancer screening-associated services after age 65, with costs exceeding $83 million.
Researchers found a 3% per year increase in cervical cancer incidence in women in their early 30s, starting from 2012, and an increase in both localized and regional disease. The study suggests that improved screening rates are needed to address the rising incidence.
Population-based cancer screening rates declined during the pandemic, only to recover rapidly in initial stages; however, long-term follow-up reveals ongoing gaps in preventive care. The study suggests that prolonged disruptions in screening can have lasting effects on public health.
The ESMO Asia Congress 2022 will focus on the latest scientific and clinical advances in oncology, with a special emphasis on the Asia-Pacific region. Media representatives can register for coverage through the official media registration form.
Researchers have identified two distinct molecular subgroups of cervical cancer, C1 and C2, which differ in their clinical aggressiveness and response to treatment. The study suggests that determining the subgroup of a patient's cervical cancer could provide additional prognostic information for planning treatment.
A new study found that sexual side effects of cancer treatment are discussed less frequently with female patients, who are asked about their sexual health 1 in 10 times, compared to 9 in 10 men. The disparity is also observed in clinical trials nationwide.
USC Norris Comprehensive Cancer Center is partnering with the Chinatown Service Center to address disparities in cervical cancer screening and treatment. The partnership aims to optimize access, shorten diagnosis-to-treatment timeframes, and enhance quality of care for Chinese and Latina women in Los Angeles.
A UTHealth Houston study found regional disparities in cancer screening rates tied to social vulnerability, with lower rates in more vulnerable counties. The study analyzed 3,141 US counties and discovered significant differences in breast, cervical, and colorectal cancer screenings.